Matches in SemOpenAlex for { <https://semopenalex.org/work/W2971330481> ?p ?o ?g. }
- W2971330481 endingPage "482" @default.
- W2971330481 startingPage "482" @default.
- W2971330481 abstract "Neutropenia is a common complication from chemotherapy. Mecapegfilgramtim (code name HHPG-19K), a long-acting recombinant human granulocyte colony-stimulating factor (rhG-CSF), has been developed. This study was to evaluate the efficacy and safety of mecapegfilgrastim for reducing neutropenia compared with filgrastim.This was a randomized, controlled non-inferiority study. A total of 339 breast cancer patients who were eligible for (neo) adjuvant chemotherapy were randomized assigned into three groups to receive mecapegfilgrastim 100 µg/kg, mecapegfilgrastim fixed dose of 6 mg or filgrastim 5 µg/kg/day in the first cycle of chemotherapy. The primary endpoint was the duration of grade ≥3 neutropenia in cycle 1. The secondary endpoints included the duration of grade ≥3 neutropenia in cycles 2-4, incidence of grade ≥3 neutropenia, and febrile neutropenia (FN). The safety profile was also evaluated.The mean duration of grade ≥3 neutropenia was 1.06 [95% confidence interval (CI): 0.65, 1.26] days in mecapegfilgrastim 100 µg/kg group, 1.23 (95% CI: 0.84, 1.88) days in mecapegfilgrastim 6 mg group, and 2.06 (95% CI: 1.66, 2.46) days in the filgrastim group. The mean difference between mecapegfilgrastim 100 µg/kg and filgrastim was -1.00 (95% CI: -1.52, -0.48), the mean difference between mecapegfilgrastim 6 mg and filgrastim was -0.83 (95% CI: -1.36, -0.30). The upper bounds of 95% CI for the difference between mecapegfilgrastim and filgrastim were all <1 day (the predefined non-inferiority margin). For the incidence of grade ≥3 and grade 4 neutropenia, the mean duration of grade 4 neutropenia, mecapegfilgrastim showed better performance compared with filgrastim. For the incidence of FN, there was no difference between patients treated with mecapegfilgrastim and filgrastim. For safety profile, mecapegfilgrastim of two doses groups were all well-tolerated. Fixed 6 mg dose of mecapegfilgrastim exhibited comparable efficacy and safety in comparison with 100 µg/kg during 4 cycles.Long-acting mecapegfilgrastim (100 µg/kg and fixed 6 mg) is very effective and well tolerated when administered in the primary prophylaxis of chemotherapy induced neutropenia and in consecutive-cycle treatment. In some clinical parameters, mecafilgrastim is non-inferior and even superior to filgrastim. The fixed 6 mg-dose regimen showed similar efficacy and safety profile compared with 100 µg/kg regimen, and would be the preference in clinical practice, due to the convenient once-per-cycle administration and high-degree treatment compliance for the patients. This study provided new evidence for the novel long-acting rhG-CSF, mecapegfilgrastim, which would be a new alternative for clinical practice for prophylaxis of chemotherapy induced neutropenia." @default.
- W2971330481 created "2019-09-05" @default.
- W2971330481 creator A5002816521 @default.
- W2971330481 creator A5003077724 @default.
- W2971330481 creator A5010453430 @default.
- W2971330481 creator A5017183298 @default.
- W2971330481 creator A5030507461 @default.
- W2971330481 creator A5045126804 @default.
- W2971330481 creator A5047981422 @default.
- W2971330481 creator A5052901056 @default.
- W2971330481 creator A5057561095 @default.
- W2971330481 creator A5076149259 @default.
- W2971330481 creator A5076833306 @default.
- W2971330481 creator A5078340473 @default.
- W2971330481 creator A5088111638 @default.
- W2971330481 date "2019-09-01" @default.
- W2971330481 modified "2023-10-14" @default.
- W2971330481 title "Efficacy and safety of mecapegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in patients with breast cancer: a randomized, multicenter, active-controlled phase III trial" @default.
- W2971330481 cites W1546909751 @default.
- W2971330481 cites W1969840975 @default.
- W2971330481 cites W1987717169 @default.
- W2971330481 cites W2014576677 @default.
- W2971330481 cites W2036450045 @default.
- W2971330481 cites W2049892213 @default.
- W2971330481 cites W2075213874 @default.
- W2971330481 cites W2096104385 @default.
- W2971330481 cites W2100082529 @default.
- W2971330481 cites W2115170812 @default.
- W2971330481 cites W2146889322 @default.
- W2971330481 cites W2163827242 @default.
- W2971330481 cites W2286238107 @default.
- W2971330481 cites W2335359483 @default.
- W2971330481 cites W2755093638 @default.
- W2971330481 cites W2943483493 @default.
- W2971330481 doi "https://doi.org/10.21037/atm.2019.07.95" @default.
- W2971330481 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7290653" @default.
- W2971330481 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32566597" @default.
- W2971330481 hasPublicationYear "2019" @default.
- W2971330481 type Work @default.
- W2971330481 sameAs 2971330481 @default.
- W2971330481 citedByCount "15" @default.
- W2971330481 countsByYear W29713304812019 @default.
- W2971330481 countsByYear W29713304812020 @default.
- W2971330481 countsByYear W29713304812021 @default.
- W2971330481 countsByYear W29713304812022 @default.
- W2971330481 countsByYear W29713304812023 @default.
- W2971330481 crossrefType "journal-article" @default.
- W2971330481 hasAuthorship W2971330481A5002816521 @default.
- W2971330481 hasAuthorship W2971330481A5003077724 @default.
- W2971330481 hasAuthorship W2971330481A5010453430 @default.
- W2971330481 hasAuthorship W2971330481A5017183298 @default.
- W2971330481 hasAuthorship W2971330481A5030507461 @default.
- W2971330481 hasAuthorship W2971330481A5045126804 @default.
- W2971330481 hasAuthorship W2971330481A5047981422 @default.
- W2971330481 hasAuthorship W2971330481A5052901056 @default.
- W2971330481 hasAuthorship W2971330481A5057561095 @default.
- W2971330481 hasAuthorship W2971330481A5076149259 @default.
- W2971330481 hasAuthorship W2971330481A5076833306 @default.
- W2971330481 hasAuthorship W2971330481A5078340473 @default.
- W2971330481 hasAuthorship W2971330481A5088111638 @default.
- W2971330481 hasBestOaLocation W29713304811 @default.
- W2971330481 hasConcept C126322002 @default.
- W2971330481 hasConcept C141071460 @default.
- W2971330481 hasConcept C168563851 @default.
- W2971330481 hasConcept C203092338 @default.
- W2971330481 hasConcept C2776694085 @default.
- W2971330481 hasConcept C2777063308 @default.
- W2971330481 hasConcept C2777767877 @default.
- W2971330481 hasConcept C2778850193 @default.
- W2971330481 hasConcept C2779171977 @default.
- W2971330481 hasConcept C71924100 @default.
- W2971330481 hasConceptScore W2971330481C126322002 @default.
- W2971330481 hasConceptScore W2971330481C141071460 @default.
- W2971330481 hasConceptScore W2971330481C168563851 @default.
- W2971330481 hasConceptScore W2971330481C203092338 @default.
- W2971330481 hasConceptScore W2971330481C2776694085 @default.
- W2971330481 hasConceptScore W2971330481C2777063308 @default.
- W2971330481 hasConceptScore W2971330481C2777767877 @default.
- W2971330481 hasConceptScore W2971330481C2778850193 @default.
- W2971330481 hasConceptScore W2971330481C2779171977 @default.
- W2971330481 hasConceptScore W2971330481C71924100 @default.
- W2971330481 hasIssue "18" @default.
- W2971330481 hasLocation W29713304811 @default.
- W2971330481 hasLocation W29713304812 @default.
- W2971330481 hasLocation W29713304813 @default.
- W2971330481 hasLocation W29713304814 @default.
- W2971330481 hasOpenAccess W2971330481 @default.
- W2971330481 hasPrimaryLocation W29713304811 @default.
- W2971330481 hasRelatedWork W1899796548 @default.
- W2971330481 hasRelatedWork W2003258318 @default.
- W2971330481 hasRelatedWork W20115109 @default.
- W2971330481 hasRelatedWork W2049625761 @default.
- W2971330481 hasRelatedWork W2058165252 @default.
- W2971330481 hasRelatedWork W2119897082 @default.
- W2971330481 hasRelatedWork W2230906093 @default.
- W2971330481 hasRelatedWork W2527816261 @default.
- W2971330481 hasRelatedWork W2958331463 @default.
- W2971330481 hasRelatedWork W2466010828 @default.